2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM). (September 2015) - Bachet, J.B.; Hammel, P.; Desrame, J.; Chibaudel, B.; Debourdeau, P.; Dauba, J.; Lecomte, T.; Seitz, J.F.; Tournigand, C.; Aparicio, T.; Guerin Meyer, V.; Taieb, J.; et al.